New Approaches to the Management of Gram-Negative Resistant Infections

New Approaches to the Management of Gram-Negative Resistant Infections

Thursday, September 13, 2018 in Troy, MI
Dinner -- Morton's-Troy, 6:30 PM EST
Boardroom A

Agenda

 

Due to high demand, please email meetings@clinicaloptions.com to request attendance. Please be sure to include the email address and degree type for each attendee as well as the city in which you are requesting attendance.

 

 

6:30 PM - 7:00 PM Registration and Dinner
7:00 PM - 8:00 PM Program

 

  • Gram-Negative Bacteria: Overview/Review
  • New Approaches to the Treatment of MDR Gram-Negative Infections
    • Novel compounds and combinations
    • Emerging testing and monitoring strategies
  • Audience Question and Answer Session

 

 

Faculty

Faculty
George H. Karam, MD

Paula Garvey Manship Chair of Medicine
Department of Medicine
LSU School of Medicine
New Orleans, Louisiana

Faculty
Marcus Zervos, MD

Division Head, Infectious Diseases
Henry Ford Hospital
Professor of Medicine
Wayne State University School of Medicine
Detroit, Michigan

CME

Goal
The goal of this activity is to improve participants’ knowledge and competence in applying current and emerging antibacterials in the management of patients with resistant Gram-negative infections.

Target Audience
This program is intended for physicians, nurse practitioners, physician assistants, registered nurses, pharmacists, and other healthcare providers who care for patients with multidrug-resistant Gram-negative infections.

Learning Objectives

  • Review the epidemiology and changing patterns of multidrug resistance of Gram-negative bacteria to include local trends and the significance of this information in clinical practice
  • Explore key clinical trial data on new and emerging therapeutic options against multidrug-resistant Gram-negative bacteria, with attention to safety, efficacy, and adverse event profiles of newer agents vs those of established agents of the same class
  • Discuss individualized management approaches to the treatment of multidrug-resistant Gram-negative infections with a focus on next-generation antimicrobial agents and their potential utility for reducing resistance and improving patient-specific administration and dosing considerations

Accreditation

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Medical Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.

A statement of credit will be issued only upon completion of the online activity evaluation form.

Provider approved by the California Board of Registered Nursing, Provider Number 13485, for 1.0 contact hours.

Pharmacist Continuing Medical Education

Credit Designation

Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - JA4008162-9999-18-118-L01-P)

Type of Activity: Knowledge

Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Disclosure of Conflicts of Interest 
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.